A new study conducted by the Northwestern University suggests that a combination of the drugs ivacaftor and lumacaftor has the ability to improve the health of patients diagnosed with a rare form of the lung disease cystic fibrosis.
A new study conducted by the Northwestern University suggests that a combination of the drugs ivacaftor and lumacaftor has the ability to improve the health of patients diagnosed with a rare form of the lung disease cystic fibrosis.
Share this Article
Recommended